Non-small cell lung cancer (NSCLC) is considered to be the primary cause of cancer-related mortalities worldwide. Paclitaxel (PTX), either as a monotherapy or in combination with other drugs, is an alternative therapy for advanced NSCLC. However, cancer cell resistance against PTX represents a major clinical problem. This study aimed to investigate the role and underlying mechanism of miR-4262 in PTX-resistant NSCLC. The levels of miR-4262 were analysed by quantitative reverse transcription polymerase chain reaction. A luciferase reporter assay and bioinformatics were used to explore the potential target gene of miR-4262. Regulation of miR-4262 and PTEN expressions in NSCLC was conducted by transfection. PTX-resistant A549 and H1299 cells were established by stepwise screening through increasing the PTX concentration in the cultures. In vivo, tumorigenesis experiments were used to explore the effects of miR-4262 and PTX. Cell proliferation, apoptosis and cell migration were detected using a CCK-8 assay, flow cytometry and Transwell migration assay, respectively. PI3 K/Akt pathway-related proteins were detected by western blot. miR-4262 expression was significantly upregulated in NSCLC tissues and cell lines, and miR-4262 targeted PTEN. In addition, miR-4262 induced PTX chemoresistance by promoting survival and migration in A549/PTX and H1299/PTX cells. Moreover, miR-4262 expression and PI3 K/Akt signalling pathway-related proteins were upregulated and PTEN was downregulated in A549/PTX and H1299/PTX. Our results indicate that miR-4262 enhances PTX resistance in NSCLC cells through targeting PTEN and activating the PI3 K/ Akt signalling pathway. The inhibition of miR-4262 expression might be an improved treatment to overcome PTX resistance in NSCLC.
Introduction
Approximately 80% of all primary lung cancer is non-small cell lung cancer (NSCLC). NSCLC is considered to be the primary cause of cancer-related mortalities worldwide [1] . Many treatments have been extensively explored in clinical applications, but systemic chemotherapy has been shown to provide unprecedented improvement in the survival rate and quality of life for patients with NSCLC [2] . Currently, paclitaxel (PTX), either as a monotherapy or in combination with other drugs, is an alternative therapy for advanced NSCLC. However, both de novo and acquired resistance to PTX frequently occur in NSCLC treatment, presenting a substantial clinical problem [3] . To improve the chemotherapeutic effect of PTX, we urgently need to explore the potential underlying mechanism of its function and develop an effective strategy to overcome the resistance of NSCLC to PTX. MicroRNAs (miRNAs) are non-coding RNA molecules consisting of approximately [20] [21] [22] [23] [24] [25] nucleotides that can cause downregulation of target protein expression by mRNA degradation or translational inhibition. miRNAs participate in various malignancies by regulating pathophysiological processes, including cell proliferation, invasion, metastasis and apoptosis [4] [5] [6] . Lu et al. [7] constructed and validated two kinds of diagnostic miRNAs in the serum of patients with lung cancer through microarray screening, indicating that miRNAs are important in patients with lung cancer. Increasingly, studies have demonstrated that miRNAs play a role in mediating the sensitivity of cancer cells to chemicals, and miRNA dysregulation may lead to the acquisition of chemoresistance [8, 9] . For instance, miR-339-5p has been shown to promote the response to PTX chemotherapy by targeting a1,2-fucosyltransferase 1 and mediating the downstream protein Lewis y [10] . Lu et al. [11] reported that upregulated miR-107 expression enhances PTX sensitivity in NSCLC by decreasing the expression level of the antiapoptotic factor Bcl-w. Among all miRNAs, miR-4262 has rarely been investigated. A previous study indicated that miR-4262 participates in acute lung injury development by regulating lung endothelial cell apoptosis [12] . However, the expression of miR-4262 and its biological functions in the resistance of NSCLC to PTX remains elusive.
Phosphatase and tensin homologue (PTEN) is located on human chromosome 10q23 and is a tumour suppressor gene [13] . It is also an inhibitor of the PI3 K/Akt pathway [14] . Reduced expression levels and mutations of PTEN are commonly observed in lung cancer [15] , although the mechanisms of PTEN mutation and loss of expression are not fully understood [16] . In addition, studies have shown that PTEN is mediated by many miRNAs. miRNA-492 expression facilitates the progression of liver cancer by targeting PTEN [17] . miRNA-221 and miRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN [18] . Moreover, studies have indicated that miR-21 and miR-26a regulate PTEN expression in NSCLC [19 -21] . However, it is unknown whether PTEN is directly related to miR-4262 in NSCLC. Therefore, it is advantageous to explore the miRNA regulatory network that is responsible for the chemoresistance of PTX in NSCLC.
In this study, we first analysed the expression levels of miR-4262 in PTX-sensitive and PTX-resistant A549 and H1299 cells and in clinical samples from patients. The level of miR-4262 was upregulated in NSCLC cell lines and lung tissues. We found that miR-4262 was responsible for PTX resistance by altering the PTEN expression level and the subsequently activated the PI3 K/AKT signalling pathway. The identification of the miR-4262/PTEN/PI3 K/AKT axis as a novel regulator that controls PTX resistance in NSCLC provides new molecular insights for the development of new therapies for PTX resistance in NSCLC.
Material and methods

Clinical specimens
Clinical specimens were obtained from patients with NSCLC at the First Affiliated Hospital of Kunming Medical University, China and consent forms were signed by all patients. Prior to specimen collection, the patients did not receive immunotherapy, chemotherapy or radiotherapy. Tissue samples were snap-frozen at 2808C until use. The procedures were approved by the Clinical Research and Ethics Committee at the First Affiliated Hospital of Kunming Medical University. In this study, NSCLC tissues and adjacent non-cancerous tissues were obtained for each individual patient.
Cell culture
The NSCLC cell lines A549 and H1299 were used in our study. The fetal lung fibroblast cell line MRC5 was used as the noncancerous control cell line. All of the above-mentioned cell lines were purchased from ATCC (Manassas, VA, USA), and these cell lines were all maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 100 mg ml 21 streptomycin and 100 U ml 21 penicillin (Sigma-Aldrich, St. Louis, MO, USA) in a humidified air atmosphere containing 5% CO 2 at 378C. PTX-resistant NSCLC cell lines (A549/PTX and H1299/ PTX) were established by stepwise screening through increasing the PTX concentration in a range of 0.1-0.5 mM over six months in the cultures. Then, PTX resistance was maintained with 0.5 mM PTX in the culture. Cellular assays were carried out when the cells were in the logarithmic growth phase.
Cell transfection
Cells in the logarithmic growth phase were subjected to cell transfection. Transient transfection of the cells with miR-4262 mimics, miR-4262 inhibitor and its NC control (Invitrogen) was conducted using Lipofectamine TM 3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA). The recombinant plasmid pcDNA3.1-PTEN was synthesized by GenePharma (Shanghai, China). The plasmids were verified using DNA sequencing and the verified vectors were further amplified for subsequent experiments. Briefly, cells were precultured to approximately 50% confluence and then transfected with the pcDNA3.1 vector or pcDNA3.1-PTEN using Lipofectamine 3000 according to the manufacturer's instructions. After 12 h of transfection, fresh medium was added to the plates for cell culture. The sequence of the miR-4262 mimics is 5 0 -GACAUUCAGACUACCUG-3 0 .
Quantitative reverse transcription PCR
Total RNA was extracted by TRIzol (Life Technologies, Carlsbad, CA, USA) following the manufacturer's protocols. cDNA was obtained from 500 ng total RNA using a PrimeScript RT kit (Epicenter, Madison, WI, USA), followed by polymerase chain reaction (PCR) amplification by an ABI Prism 7500 Sequence Detector System (Applied Biosystems, Foster City, CA, USA) using SYBR Premix Ex Taq (TaKaRa, Tokyo, Japan). The RNA expression levels of the target genes and miRNA were normalized to those of GAPDH and U6, respectively, by the 2 2DDCt method. 
Flow cytometry analysis
The cells were collected, rinsed and resuspended in phosphate-buffered saline (PBS) and then stained with annexin V and propidium iodide (PI) using an Annexin V-FITC/PI Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer's protocol. The percentage of apoptotic cells was determined by a FACS Calibur flow cytometer (BD Biosciences). FlowJo 6.0 software was used for data analysis. The procedures were performed in triplicate.
Migration assay
Transwell chambers (Corning) were used for the cell migration assay following the manufacturer's instructions. Migration chambers were purchased from Corning. These chambers were placed into a 24-well plate. A filter membrane in the upper chamber (Transwell insert) separates it from the lower chamber [22] . Cells are seeded in the upper chamber and cells migrate through the membrane to the lower chamber of the culture plate that contains chemotactic stimuli (serum is often used) [23] . Thus, cells can migrate to the serum-containing side. Briefly, A549 and H1299 cells in extracellular matrix (ECM) chambers (2 Â 10 4 cells well
21
) were cultured. Serum-free Dulbecco's modified Eagle medium (DMEM) (300 ml) was added to the ECM layer, which was allowed to hydrate for 1 h. Then the cells were resuspended in L-DMEM and allowed to adhere for 1 h. Migration medium containing vectors from the various groups was added to the bottom chamber. After 12 h incubation, cells in the lower chamber were fixed in 100% methanol for 30 min and then stained with 0.1% crystal violet for 20 min at room temperature. Subsequently, the cells were microscopically observed and counted in five random fields of view, and the migrated cell numbers were counted.
Dual-luciferase reporter assay
Putative binding sites were identified by the TargetScan algorithm. miR-4262 binding sites on the wild-type PTEN 3 0 untranslated region (UTR) and the mutant PTEN 3 0 -UTR were inserted into a pGL3-report luciferase reporter vector (Sigma-Aldrich, St. Louis, MO, USA). Then the miR-4262 mimics and control miRNA were cotransfected into cells with pGL3-3 0 -UTR wild-type or mutant plasmid DNA by Lipofectamine 3000 following the manufacturer's instructions. After 24 h of transfection, the relative luciferase activity was analysed using a Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA), with Renilla luciferase reference plasmid normalization.
Tumour xenograft model
The animal experiments were approved by Kunming Medical University. A549/PTX cells were suspended, mixed with Matrigel (BD Biosciences, San Jose, CA, USA) and injected subcutaneously into the posterior flanks of each anaesthetized nude mouse (five weeks, 18 -20 g). When the tumour volume reached approximately 100 mm 3 , PTX alone or PTX combined with the miRNA-4262 antagomir was injected intravenously into the mice every other day for 30 days. The development of the tumour was closely monitored by calipers, and the tumour volume was calculated according to the following formula: volume ¼ . After the tumours grew to the desired size, the mice were euthanized, and the tumours were extracted and weighted. Then, miR-4264 and specific proteins in tumour sections were evaluated by quantitative reverse transcription PCR (qRT-PCR) or western blot.
Statistical analysis
Continuous data are presented as the mean + s.e.m. Statistical analysis of the human samples was performed using royalsocietypublishing.org/journal/rsob Open Biol. royalsocietypublishing.org/journal/rsob Open Biol. 9: 180227 SPSS 17.0 software (SPSS, Chicago, IL, USA) and GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). A two-tailed unpaired Student's t-test was used for data analysis. p , 0.05 was considered to indicate a statistically significant difference. royalsocietypublishing.org/journal/rsob Open Biol. 9: 180227 miR-4262 were markedly upregulated by the miR-4262 mimics and downregulated by the miR-4262 inhibitor in A549 and H1299 cells (figure 2a). We subsequently investigated the potential role of miR-4262 in cell viability via a CCK-8 assay. As shown in figure 2b , the upregulated miR-4262 level significantly promoted NSCLC cell viability. By contrast, the miR-4262 inhibitor significantly inhibited the viability of A549 and H1299 cells. To further investigate the cell proliferation, the expression of Ki-67 was detected by western blot. The results showed that the expression of Ki-67 was significantly increased in the miR-4262 mimics group and decreased in the miR-4262 inhibitor group compared with the miR-NC group (figure 2c). Cell apoptosis of A549 and H1299 was measured by flow cytometry after being transfected with the miR-4262 mimics and inhibitor, respectively. As shown in figure 2d , the proportion of apoptotic cells among A549 cells treated with the miR-4262 inhibitor compared with miR-NC was increased. In addition, similar results were observed in H1299 cells (figure 2e). By contrast, the proportion of apoptotic cells among A549 and H1229 cells transfected with the miR-4262 mimics compared with the miR-NC group was reduced. Cell migration is an important characteristic of cancer cell metastasis. Thus, we also investigated the influence of miR-4262 upregulation and downregulation on cell migration. Increased A549 and H1229 cell migration was observed after transfection with the miR-4262 mimics, whereas A549 and H1299 cell migration in the miR-4262 inhibitor group was decreased ( figure 2f,g ).
The prediction of PTEN as a target of miR-4262
miRNAs regulate many biological functions by downregulating downstream targets of expression. We identified PTEN as a target of miR-4262 using the online bioinformatics tool Target Scan. The complementary structure of miRNA-4262 is shown in figure 3a . To further confirm the interaction between miR-4262 and PTEN, a luciferase reporter gene vector was constructed with the downstream target luciferase gene PTEN-3 0 -UTR-WT and PTEN-3 0 -UTR-Mut. We observed a marked decrease in the PTEN WT-3 0 UTR/miR-4262 group compared with the PTEN MUT-3 0 UTR/miR-4262 group (figure 3b). To further investigate whether PTEN in NSCLC cells is modulated by miR-4262, A549 and H1299 cells were transfected with the miR-4262 mimics or inhibitor. Then, the mRNA and protein levels of PTEN were examined. In both A549 and H1229 cells, the mRNA expression level of PTEN significantly decreased after the cells were treated with the miR-4262 mimics and significantly increased after the cells were treated with the miR-4262 inhibitor ( figure 3c,d ). In addition, cotreatment with the miR-4262 mimics and pcDNA3.1-PTEN significantly enhanced PTEN knockdown in both A549 and H1299 cells, compared with pcDNA3. 1-PTEN (figure 3e,f ) . The results demonstrate that miR-4262 targets to PTEN. What is more, knockdown of PTEN by specific siRNAs had no effect on miR-4262 expression (electronic supplementary material, figure S1A,B) . royalsocietypublishing.org/journal/rsob Open Biol. 9: 180227 miR-4262 increases sensitivity of parental cells to PTX, A549 and H1299 cells were treated with miR-4262 inhibitor. Knocking down the expression of miR-4262 increases the sensitivity of parental cells to PTX (figure 5e,f ). Also downregulation of PTEN by siRNA decreased the cell apoptosis in PTX-treated A549 and H1299 cell lines (electronic supplementary material, figure S1C ). In addition, the number of migrated cells among the pcDNA3.1-PTEN þ miR-mimics group increased when compared with the pcDNA3.1-PTEN group ( figure 6a,b) . Previous studies have shown that the PTEN/ PI3 K -AKT axis is involved in drug resistance in NSCLC [24] . In this study, the western blot assays revealed that pcDNA3.1-PTEN transfection notably increased the PTEN expression level, compared with the PTX þ NC group, while this effect was abolished by the miR-4262 mimics (figure 6c). Moreover, overexpression of PTEN reduced pAkt, p-GSK-3b expression levels in both cell lines; however, as shown in figure 6c, this effect was abated by the miR-4262 mimics. These data suggest that miR-4262 induced PTX chemoresistance by promoting survival and migration through the regulation of PTEN expression in A549/PTX and H1299/PTX cells. royalsocietypublishing.org/journal/rsob Open Biol. 9: 180227 3.6. miR-4262 facilitates PTX resistance in vivo
To further validate our findings in vivo, we established PTXresistant xenograft by injecting A549/PTX cells. As shown in figure 7a ,b, in the A549/PTX xenograft model, the tumour volume in the mice that received an intravenous injection of PTX or the miR-4262 antagomir was smaller than that in the control group, and cotreatment with PTX and miR-4262 antagomir inhibited tumour growth markedly. In addition, the mean tumour weight in the miR-antagomir group was considerably less than that in the control groups. In addition, the tumour weight in the miR-antagomir þ PTX group was the lowest among all the groups (figure 7c). In the tumour tissue sample, compared with the control treatment, treatment with an individual therapy markedly increased the PTEN expression level and miR-4262 antagomir reduced the expression of miR-4262 and PTX increased the expression of miR-4262 (figure 7d ). Western blot analysis showed that p-Akt, p-GSK-3b protein expression levels were decreased in the miR-4262 antagomir group compared with the control group. The combination therapy indicated the synergistic inhibition of p-Akt, p-GSK-3b expression and promotion of Bax and cleaved caspase 3 expression (figure 7e,f ). Overall, these results reveal that the miR-4262 antagomir inhibited tumour growth in PTX-resistant NSCLC tissues in vivo.
Discussion
Although a number of new chemotherapeutic agents (including PTX and cisplatin) have been used for the treatment of NSCLC over the past decade, drug resistance has remained a major factor that influences the efficacy of chemotherapy [25, 26] . There is ample evidence that miRNAs play a crucial role in cancer chemotherapeutic resistance; thus, miRNAs can potentially be used to reverse drug resistance [27, 28] . Several studies have revealed the role of various miRNAs, including miR-135a [29] , miR-337-3p [30] and miR-7 [31] , in modulating the sensitivity of NSCLC cells to PTX chemotherapy. However, the underlying mechanism of miRNAregulated chemotherapeutic resistance is not fully understood. In this study, we explored the role of miR-4262 in PTX resistance in NSCLC.
Numerous studies have reported that miR-4262 acts as an oncogene in many types of cancers. For example, Zhang et al. [32] found that miR-4262 promotes cell proliferation in human cutaneous malignant melanoma cells. miR-4262 has been shown to regulate hepatocellular carcinoma cell survival and apoptosis by activating the NF-kB pathway [33] . Moreover, a recent study showed that miR-4262 facilitates the invasion of osteosarcoma cells via osteopontin modification [34] . In addition, miR-4262 is involved in the progression of acute lung injury by regulating pulmonary endothelial cell apoptosis [35] . Despite the pathogenic effects of miR-4262 on various diseases, the expression and effects of miR-4262 in NSCLC remain unclear.
In our study, we first proposed the effects of miR-4262 on regulating NSCLC functions. Our results confirmed the upregulation of miR-4262 expression in A549/PTX and H1299/PTX cells and in their parent cells. miR-4262 increased NSCLC cell migration and promoted cell viability; thus, miR-4262 was considered an oncogene. The inhibition of miR-4262 caused sensitivity of the A549/PTX and H1299/PTX cell lines to PTX, demonstrating that miR-4262 is a key mediator of chemical resistance in NSCLC cells. Furthermore, coadministration of the miR-4262 antagomir reduced the tumour growth inhibition of PTX in A549/ PTX xenografts, suggesting that miR-4262 modulates chemoresistance in vivo.
To explore the mechanism of miR-4262 in regulating PTX resistance in NSCLC, we predicted the target genes of miR-4262 through bioinformatics analysis. Our experimental results indicated that miR-4262 directly binds to the 3 0 -UTR of PTEN. PTEN is expressed at low levels in NSCLC [15] , and its downregulation is associated with accelerated lung cancer growth and increased invasion [21] . More importantly, PTEN is also involved in drug resistance in NSCLC. For instance, aberrant expression of miR-328 causes cisplatin resistance by targeting PTEN in NSCLC [36] . miR-181 mediates cisplatin resistance in NSCLC through the PTEN/PI3 K/AKT pathway [37] . Consistent with these findings, we found that the upregulation of PTEN expression promotes cell apoptosis and represses cell migration in A549/PTX and H1299/PTX cells. We also observed an inverse correlation between miR-4262 and PTEN in NSCLC in vitro and in vivo. miR-4262 acts on PTX resistance in NSCLC by altering its target PTEN expression levels and activating the PI3 K/Akt signalling pathway. However, our current findings require further investigation and the role of other miRNAs in PTX resistance requires further investigation.
Conclusion
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